As scientists are identifying molecular alterations in patients with later-stage cancers that may be targets in earlier-stage disease, next-generation sequencing is being utilized more in the first-line setting, noted Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.
As scientists are identifying molecular alterations in patients with later-stage cancers that may be targets in earlier-stage disease, next-generation sequencing is being utilized more in the first-line setting, noted Sigrun Hallmeyer, MD, medical oncologist with Advocate Health.
Hallmeyer was a presenter of the day 1 workshop, “Precision Medicine,” at the 49th Association of Community Cancer Centers’ 49th Annual Meeting and Cancer Center Business Summit.
Transcript
What are some best practices clinics can utilize to identify patients suitable for a precision medicine course of treatment?
The current indications for the medications that have been approved in the setting of oncology, that are based on precision medicine and molecular testing, have really been established in the advanced-stage setting: stage IV, metastatic disease, and oftentimes in lines that have exceeded standard of care. So when patients are believed to no longer benefit from standard of care is when typically these molecular studies are ordered and then the more experimental therapies are being utilized in that setting.
That is changing, though, as we are identifying these targets in patients in the later-stage settings that could potentially make a significant impact if we were to utilize the medications that are attached to these molecular alterations sooner in the trajectory. And so in that, you’re identifying a bit of a shift in when physicians actually utilize, for instance, next-generation sequencing, where there’s, probably more now, a push in using that earlier and earlier in the trajectory of the disease. And I would say probably in the majority of practices now, these are done in the first-line setting when patients are ultimately identified with advanced disease or stage IV disease.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More
Breast Cancer Treatment Disparities Impact Survival Based on Race, Age, Socioeconomics
May 9th 2024A new study has linked racial and ethnic disparities with factors like age, income, and insurance to breast cancer treatment decline. Patients who received all treatments had better survival, highlighting the need for interventions to improve access and reduce disparities.
Read More